Esketamine PK Bridge

Solvonis Therapeutics (LSE:SVNS) has made significant progress in advancing its SVN-002 programme for moderate to severe alcohol use disorder. CEO Anthony Tennyson announced positive bridging pharmacokinetic data, demonstrating that esketamine delivered sublingually or bucally provides comparable exposure levels as intranasal administration. This is a crucial step in establishing the scientific bridge required by the FDA via the 505(b)(2) pathway.